Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 63 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Empoderar a las personas con cáncer: preguntas y respuestas con la... June 8, 2021 Touching a nerve: How neuroscience could advance our understanding of cancer December 1, 2021 Resource Round-Up: 2Unstoppable May 16, 2023 New Type of Chemotherapy Bypasses Healthy Cells to Decrease Negative Side... December 5, 2019 Load more HOT NEWS FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer A bug in the system – the difficulties of linking the... Lung Adenocarcinoma with Mucinous Histology 20 years on: how we’ve decreased cancer death rates
